Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors

Wang,Qingfei; Ding,Hui; Liu,Baorui; Li,Shau-Hsuan; Li,Ping; Ge,Hailiang; Zhang,Kui

doi:10.3892/ijo.2014.2271

Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors

Authors:
- Qingfei Wang
- Hui Ding
- Baorui Liu
- Shau-Hsuan Li
- Ping Li
- Hailiang Ge
- Kui Zhang
View Affiliations

Affiliations: Department of Laboratory Medicine, Nanjing Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing 210008, P.R. China, The Comprehensive Cancer Center, Nanjing Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing 210008, P.R. China, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA, Department of Immunology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, P.R. China
Published online on: January 21, 2014 https://doi.org/10.3892/ijo.2014.2271
Pages: 1277-1283

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Trastuzumab resistance is a challenging problem in ErbB2/HER2-positive breast cancers. Multiple mechanisms of resistance have been proposed and, thus, may require the development of more personalized therapies. In this study, we report the establishment of a mouse mammary cancer cell line, designated MT104T, obtained from spontaneous tumors in genetically engineered FVB/N-ErbB2/Neu-positive-PTEN-deficient mice. The critical molecular phenotype of MT104T cells was confirmed by genotyping and western blot analysis. This cell line was tumorigenic in immunologically intact syngeneic mice, forming tumors of generally similar histology as its origin. PTEN loss led to hyperactivation of Akt and conferred resistance to anti-ErbB2/Neu antibody treatment in MT104T cells. Addition of the Akt inhibitor triciribine (TCN) inhibited the viability of MT104T cells in a dose- and time-dependent manner as evaluated by MTT assay. ErbB2/Neu antibody and TCN combination treatment greatly induced apoptosis of MT104T cells as indicated by Annexin V-FITC staining. Moreover, this combination treatment also significantly reduced both Akt and Erk activities, which are responsible for the inhibitory effect on MT104T cells. Therefore, MT104T cells could represent an alternative model system to investigate the nature of ErbB2‑positive breast cancer and for the experimental therapeutics studies of this disease. Our findings also suggest that combination of TCN may be a potential strategy for the treatment of trastuzumab-resistant breast cancer mediated by PTEN loss or PI3K hyperactivation, which may facilitate the development of more personalized therapies for breast cancer patients.

View Figures

View References

1.	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2.	Network CGA: Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
3.	Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
4.	Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
5.	Sotiriou C and Piccart MJ: Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer. 7:545–553. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
7.	Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
8.	Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005. View Article : Google Scholar : PubMed/NCBI
9.	Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
10.	Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 20:719–726. 2002. View Article : Google Scholar : PubMed/NCBI
11.	Lan KH, Lu CH and Yu D: Mechanisms of trastuzumab resistance and their clinical implications. Ann NY Acad Sci. 1059:70–75. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Zhang S, Huang WC, Li P, et al: Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 17:461–469. 2011. View Article : Google Scholar : PubMed/NCBI
13.	Gajria D and Chandarlapaty S: HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
14.	Nahta R, Yu D, Hung MC, Hortobagyi GN and Esteva FJ: Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 3:269–280. 2006. View Article : Google Scholar : PubMed/NCBI
15.	Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 12:395–402. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Di Cristofano A and Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell. 100:387–390. 2000.PubMed/NCBI
17.	Hollander MC, Blumenthal GM and Dennis PA: PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 11:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Esteva FJ, Guo H, Zhang S, et al: PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 177:1647–1656. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Fujita T, Doihara H, Kawasaki K, et al: PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer. 94:247–252. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 6:117–127. 2004. View Article : Google Scholar : PubMed/NCBI
21.	Alvarez RH, Valero V and Hortobagyi GN: Emerging targeted therapies for breast cancer. J Clin Oncol. 28:3366–3379. 2010. View Article : Google Scholar : PubMed/NCBI
22.	Wang Q, Li SH, Wang H, et al: Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res. 72:4417–4428. 2012. View Article : Google Scholar : PubMed/NCBI
23.	Andrechek ER, Hardy WR, Siegel PM, Rudnicki MA, Cardiff RD and Muller WJ: Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci USA. 97:3444–3449. 2000. View Article : Google Scholar : PubMed/NCBI
24.	Dourdin N, Schade B, Lesurf R, et al: Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res. 68:2122–2131. 2008. View Article : Google Scholar : PubMed/NCBI
25.	Ursini-Siegel J, Rajput AB, Lu H, et al: Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development. Mol Cell Biol. 27:6361–6371. 2007. View Article : Google Scholar : PubMed/NCBI
26.	Zhang H, Wang Q, Montone KT, et al: Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Exp Mol Pathol. 67:15–25. 1999. View Article : Google Scholar : PubMed/NCBI
27.	Frese KK and Tuveson DA: Maximizing mouse cancer models. Nat Rev Cancer. 7:645–658. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Vargo-Gogola T and Rosen JM: Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 7:659–672. 2007. View Article : Google Scholar : PubMed/NCBI
29.	Gopinathan A and Tuveson DA: The use of GEM models for experimental cancer therapeutics. Dis Model Mech. 1:83–86. 2008. View Article : Google Scholar
30.	Schade B, Rao T, Dourdin N, et al: PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J Biol Chem. 284:19018–19026. 2009. View Article : Google Scholar : PubMed/NCBI
31.	Mittelman A, Casper ES, Godwin TA, Cassidy C and Young CW: Phase I study of tricyclic nucleoside phosphate. Cancer Treat Rep. 67:159–162. 1983.PubMed/NCBI
32.	Hoffman K, Holmes FA, Fraschini G, et al: Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer. Cancer Chemother Pharmacol. 37:254–258. 1996. View Article : Google Scholar : PubMed/NCBI
33.	Garrett CR, Coppola D, Wenham RM, et al: Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs. 29:1381–1389. 2011. View Article : Google Scholar
34.	Evangelisti C, Ricci F, Tazzari P, et al: Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. J Cell Physiol. 226:822–831. 2011. View Article : Google Scholar
35.	Lu CH, Wyszomierski SL, Tseng LM, et al: Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res. 13:5883–5888. 2007. View Article : Google Scholar : PubMed/NCBI
36.	Balasis ME, Forinash KD, Chen YA, et al: Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res. 17:2852–2862. 2011. View Article : Google Scholar
37.	Dieterle A, Orth R, Daubrawa M, et al: The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int J Cancer. 125:932–941. 2009. View Article : Google Scholar
38.	Voskoglou-Nomikos T, Pater JL and Seymour L: Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res. 9:4227–4239. 2003.PubMed/NCBI
39.	Park S, Jiang Z, Mortenson ED, et al: The therapeutic effect of anti-HER2neu antibody depends on both innate and adaptive immunity. Cancer Cell. 18:160–170. 2010. View Article : Google Scholar
40.	Ferris RL, Jaffee EM and Ferrone S: Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 28:4390–4399. 2010. View Article : Google Scholar